We have another highly effective COVID vaccine, based on different tech

The company says it can produce 150 million doses per month by the end of the year, and the vaccine is stable when stored with normal refrigeration, so it could play a big part in the effort to administer vaccines outside of industrialized nations.So far, US citizens have had the choice of RNA-based vaccines, like the offerings from Moderna and Pfizer/BioNTech, or a vaccine based on a harmless virus engineered to carry the coronavirus spike protein, as used in the Johnson & Johnson vaccine. (This processing can involve chemically linking sugars or cleaving off superfluous parts of the protein.) The activity ensures that the purified protein will be chemically identical to the spike protein found on the surface of the SARS-CoV-2 virus itself.The company's description of the vaccine development from here on out is a bit vague, but it appears that the vaccine builds a large complex of proteins that includes multiple copies of the spike protein. While the analysis involved a smaller number of cases, it appears that NVX-CoV2373 is also highly effective against this and other variants.Side effects were generally similar to other vaccines, with headaches, fatigue, and pain at the injection site being common.This all suggests that Novavax will have little trouble gaining an Emergency Use Authorization when it applies for one from the Food and Drug Administration.